FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Drug Test Anal / Biomarker ratios.
Drug testing and analysis2022; 14(5); 983-990; doi: 10.1002/dta.3250

Biomarker ratios.

Abstract: The concept of biomarker measurements in the form of a ratio has not been explored in detail. This is surprising considering the current and future potential for biomarkers incorporating endogenous reference compounds (ERCs) in a range of fields. A selection of these relating to clinical and forensic applications, human antidoping, equine antidoping and veterinary residues are discussed.
© 2022 John Wiley & Sons, Ltd.
Get Full Text
Publication Date: 2022-03-20 PubMed ID: 35293161DOI: 10.1002/dta.3250Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research study investigates the unexplored terrain of using biomarker measurements in a ratio formation, incorporating endogenous reference compounds (ERCs). These biomarker ratios can be potentially useful across diverse fields like clinical applications, forensics, human and equine anti-doping, and veterinary residues.

Understanding the Concept

  • The study delves into an under-studied concept of using biomarker measurements in ratio formations. A biomarker is a biological characteristic that can be objectively measured and evaluated. In this context, the study refers to biomarkers incorporating endogenous reference compounds (ERCs), which are compounds that naturally occur within an organism’s body.

Potential Applications

  • The research investigates various areas where these biomarker ratios could hold significant applicability. These include clinical applications, where they could aid in diagnosing diseases or evaluating a patient’s response to treatment. They can also be useful in forensic applications for determining substances or compounds in human bodies during autopsies or crime scene analysis.
  • The potential applicability extends to human and equine anti-doping. In this context, they could be used to monitor the use of prohibited substances in athletes or racing horses, thereby ensuring fair competition.
  • Finally, they may find use in testing for veterinary residues, particularly in the food industry. This could involve detecting any residual substances in animal products that may potentially harm human consumers.

Significance of the Study

  • The study’s significance lies in its exploration of a largely uncharted area of scientific research. By proposing the concept of biomarker ratios and highlighting their potential usage across varied fields, it opens up new avenues for future research and development. This could eventually contribute to significant advancements in clinical medicine, forensics, anti-doping measures, and food safety regulations.

Cite This Article

APA
Cawley A, Keen B, Tou K, Elbourne M, Keledjian J. (2022). Biomarker ratios. Drug Test Anal, 14(5), 983-990. https://doi.org/10.1002/dta.3250

Publication

Drug testing and analysis
ISSN: 1942-7611
NlmUniqueID: 101483449
Country: England
Language: English
Volume: 14
Issue: 5
Pages: 983-990

Researcher Affiliations

Cawley, Adam
  • Australian Racing Forensic Laboratory, Racing NSW, Sydney, New South Wales, Australia.
Keen, Bethany
  • Centre for Forensic Science, University of Technology Sydney, Sydney, New South Wales, Australia.
Tou, Kathy
  • Centre for Forensic Science, University of Technology Sydney, Sydney, New South Wales, Australia.
Elbourne, Madysen
  • Centre for Forensic Science, University of Technology Sydney, Sydney, New South Wales, Australia.
Keledjian, John
  • Australian Racing Forensic Laboratory, Racing NSW, Sydney, New South Wales, Australia.

MeSH Terms

  • Animals
  • Biomarkers
  • Horses
  • Substance Abuse Detection

References

This article includes 76 references
  1. Cawley AT, Keledjian J. Intelligence-based anti-doping from an equine biological passport. Drug Test Anal 2017;9:1441-1447.
  2. Harris EK, Kanofsky P, Shakarji G, Cotlove E. Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. II. Estimating biological components of variation. Clin Chem 1970;16:1022-1027.
  3. Harris EK. Effects of intra- and interindividual variation on the appropriate use of normal ranges. Clin Chem 1974;20:1535-1542.
  4. Harris EK. Some theory of reference values. I. Stratified (categorized) normal ranges and a method for following an individual's clinical laboratory values. Clin Chem 1975;21:1457-1464.
  5. Harris EK, Cooil BK, Shakarji G, Williams GZ. On the use of statistical models of within-person variation in long-term studies of healthy individuals. Clin Chem 1980;26:383-391.
  6. Harris EK, Yasaka T. On the calculation of a “reference change” for comparing two consecutive measurements. Clin Chem 1983;29:25-30.
  7. Winkel P, Lyngbye J, Jorgensen K. The normal region-a multivariate problem. Scand J Clin Lab Invest 1972;30:339-344.
  8. Solberg HE. Multivariate reference regions. Scand J Clin Lab Invest 1995;55(Suppl. 222):3-5.
  9. Boeniger MF, Lowry LK, Rosenberg J. Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review. Am Ind Hyg Assoc J 1993;54:615-627.
  10. Kennedy M. Interpreting postmortem drug analysis and redistribution in determining cause of death: a review. Pathol Lab Med Int 2015;7:55-62.
  11. Saccenti E, Hoefsloot HCJ, Smilde AK, Westerhuis JA, Hendriks MMWB. Reflections on univariate and multivariate analysis of metabolomics data. Metabolomics 2014;10:361-374.
  12. Velden MGM, Rinaldo P, Elvers B, Hendersen M, Walter JH, Prinsen BH. The proline/citrulline ratio as a biomarker for OAT deficiency in early infancy. JIMD Rep 2012;6:95-99.
  13. Petersen A-K, Krumsiek J, Wägele B. On the hypothesis-free testing of metabolite ratios in genome-wide and metabolome-wide association studies. BMC Bioinformatics 2012;13:120.
  14. Shackleton CHL. Profiling steroid hormones and urinary steroids. J Chromatogr 1986;379:91-156.
  15. Brooks RV, Jeremiah G, Webb WA, Wheeler M. Detection of anabolic steroid administration to athletes. J Steroid Biochem 1979;11:913-917.
  16. Kicman AT, Cowan DA. Subject-based profiling for the detection of testosterone administration in sport. Drug Test Anal 2009;1:22-24.
  17. Donike M, Bärwald KR, Klosterman K, Schänzer W, Zimmermann J. Nachweis von exogenem Testosteron. 1983:293-298.
  18. Donike M, Rauth S, Mareck-Engelke U, Geyer H, Nitschke R. Evaluation of longitudinal studies, the determination of subject-based reference ranges of the testosterone/epitestosterone ratio. 1994:33-39.
  19. Baenziger J, Bowers LD. Variability of T/E ratios in athletes. 1994:41-52.
  20. Donike M, Mareck-Engelke U, Rauth S. Statistical evaluation of longitudinal studies, part 2: the usefulness of subject based reference ranges. 1995:157-165.
  21. Kicman AT. Biochemical and physiological aspects of endogenous androgens. 2010:53-54.
  22. Ayotte C, Goudreault D, Charlebois A. Testing for natural and synthetic anabolic agents in human urine. J Chromatogr B 1996;687:3-25.
  23. Mareck U, Geyer H, Opfermann G, Thevis M, Schänzer W. Factors affecting the steroid profile in doping control analysis. J Mass Spectrom 2008;43:877-891.
  24. Norli HR, Esbensen K, Westad F, Birkeland KI, Hemmersbach P. Chemometric evaluation of urinary steroid profiles in doping control. J Steroid Biochem Mol Biol 1995;54:83-88.
  25. Van Renterghem P, Sottas PE, Saugy M, Van Eenoo P. Statistical discrimination of steroid profiles in doping control with support vector machines. Anal Chim Acta 2013;768:41-48.
  26. Sottas PE, Baume N, Saudan C, Schweizer C, Kamber M, Saugy M. Bayesian detection of abnormal values in longitudinal biomarkers with an application to the T/E ratio. Biostatistics 2007;8:285-296.
  27. Sottas PE, Saudan C, Schweizer C, Baume N, Mangin P, Saugy M. From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Sci Int 2008;174:166-172.
  28. Vernec AR. The Athlete Biological Passport: an integral element of innovative strategies in antidoping. Br J Sports Med 2014;48:817-819.
  29. Boccard J, Badoud F, Grata E. A steroidomic approach for biomarkers discovery in doping control. Forensic Sci Int 2011;213:85-94.
  30. Dehennin L, Lafarge P, Dailly P, Bailloux D, Lafarge J-P. Combined profile of androgen glucuro- and sulfoconjugates in postcompetition urine of sportsmen: a simple screening procedure using gas chromatography-mass spectrometry. J Chromatogr B 1996;687:85-91.
  31. Esquivel A, Alechaga E, Monfort N, Ventura R. Sulfate metabolites improve retrospectivity after oral testosterone administration. Drug Test Anal 2019;11:392-402.
  32. Saad K, Vonaparti A, Athanasiadou I. Population reference ranges of urinary endogenous sulfate steroids concentrations and ratios as complement to the steroid profile in sports antidoping. Steroids 2019;152:108477.
  33. Forsdahl G, Zanitzer K, Erceg D, Gmeiner G. Quantification of endogenous steroid sulfates and glucuronides in human urine after intramuscular administration of testosterone esters. Steroids 2020;157:108614.
  34. Schulze J, Pettersson-Bohlin K, Thörngren J-O, Ekström L. Re-evaluation of combined ((ES/EG)/(TS/TG)) ratio as a marker of testosterone intake in men. Drug Test Anal 2021;13:1576-1579.
  35. De Wilde L, Van Renterghem P, Van Eenoo P. Long-term stability study and evaluation of intact steroid conjugate ratios after the administration of endogenous steroids. Drug Test Anal 2021.
    doi: 10.1002/dta.3096google scholar: lookup
  36. Spencer K. Analytical reviews in clinical biochemistry: the estimation of creatinine. Ann Clin Biochem 1986;23:1-25.
  37. Kicman AT, Miell JP, Teale JD. Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH. Clin Endocrinol (Oxf) 1997;47:43-50.
  38. Bidlingmaier M, Suhr J, Ernst A. High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clin Chem 2009;55:445-453.
  39. Tan SH, Lee A, Pascovici D. Plasma biomarker proteins for detection of human growth hormone administration in athletes. Sci Rep 2017;7:10039.
  40. Sieckmann T, Elmongy H, Ericsson M, Bhuiyan H, Lehtihet M, Ekström L. Longitudinal studies of putative growth hormone (GH) biomarkers and hematological and steroidal parameters in relation to 2 weeks administration of human recombinant GH. Drug Test Anal 2020;12:711-719.
  41. Krug O, Kutscher D, Piper T, Geyer H, Schänzer W, Thevis M. Quantifying cobalt in doping control urine samples-a pilot study. Drug Test Anal 2014;6:1186-1190.
  42. Thevis M, Machnik M, Schenk I. Nickel in equine sports drug testing - pilot study results on urinary nickel concentrations. Rapid Commun Mass Spectrom 2016;30:982-984.
  43. Thevis M, Thomas A, Beuck S, Butch A, Dvorak J, Schänzer W. Does the analysis of the enantiomeric composition of clenbuterol in human urine enable the differentiation of illicit clenbuterol administration from food contamination in sports drug testing?. Rapid Commun Mass Spectrom 2013;27:507-512.
  44. Parr MK, Blokland MH, Liebetrau F. Distinction of clenbuterol intake from drug or contaminated food of animal origin in a controlled administration trial-the potential of enantiomeric separation for doping control analysis. Food Addit Contam Part A 2017;34:525-535.
  45. Dolores HM, Villaseñor A, Piña OS. Evaluation of R- (−) and S- (+) clenbuterol enantiomers during a doping cycle or continuous ingestion of contaminated meat using chiral liquid chromatography by LC-TQ-MS. Drug Test Anal 2019;11:1238-1247.
  46. Houghton E, Ginn A, Teale P, Dumasia MC. Detection of the administration of anabolic preparations of nandrolone to the entire male horse. Equine Vet J 1986;18:491-493.
  47. Houghton E, Ginn A, Teale P, Dumasia MC. Testosterone administration to the colt: approaches to the problem. 1988:495-498.
  48. Bonnaire Y, Dehennin L, Plou P, Toutain PL. Testosterone administration to mares: criteria for detection of testosterone abuse by analysis of metabolites in plasma and urine. J Anal Toxicol 1995;19:175-181.
  49. International Federation of Horseracing Authorities. International Agreement on Breeding, Racing and Wagering-Article 6. IFHA 2021.
  50. Viljanto M, Scarth J, Hincks P. Application of testosterone to epitestosterone ratio to horse urine-a complimentary approach to detect the administrations of testosterone and its pro-drugs in Thoroughbred geldings. Drug Test Anal 2017;9:1328-1336.
  51. Viljanto M, Hincks P, Hillyer L. Monitoring dehydroepiandrosterone (DHEA) in the urine of Thoroughbred geldings for doping control purposes. Drug Test Anal 2018;10:1518-1527.
  52. Popot MA, Garcia P, Dehennin L. ACTH administration and detection in the horse. 1998:131-138.
  53. de Kock SS, Mandy K, Martinovic ST, Jogi P, Guthrie AJ. A study of paracetamol, orthocetamol and metacetamol in horseracing in southern Africa. 2009:363-369.
  54. Ishii H, Obara T, Kijima-Suda I. Investigation of plasma concentrations of paracetamol, metacetamol, and orthocetamol in Japanese racehorses using liquid chromatography-electrospray ionisation-tandem mass spectrometry. Drug Test Anal 2020;12:929-937.
  55. Ishii H, Obara T, Kusano K, Kijima-Suda I. Quantitative analysis of paracetamol, metacetamol, and orthocetamol in equine urine from racehorses in Japan using liquid chromatography-electrospray ionization-tandem mass spectrometry. Drug Test Anal 2020;12:1196-1202.
  56. Pesko B, Habershon-Butcher J, Muir T. Pharmacokinetics of paracetamol in the thoroughbred horse following an oral multi-dose administration. J Vet Pharmacol Therap 2022;45:54-62.
  57. Tou K, Cawley A, Bowen C, Sornalingam K, Fu S. Measurements of hydrocortisone and cortisone for longitudinal profiling of equine plasma by LC-MS/MS. Drug Test Anal 2022.
    doi: 10.1002/dta.3244google scholar: lookup
  58. Popot MA, Houghton E, Ginn A. Cortisol concentrations in post competition horse urine: a French and British survey. Equine Vet J 1997;29:226-229.
  59. Wong JKY, Wan TSM. Doping control analyses in horseracing: a clinician's guide. Vet J 2014;200:8-16.
  60. Wynne PM, Vine JH, Amiet RG. 3-Methoxytyramine as an indicator of dopaminergic manipulation in the equine athlete. J Chromatogr B 2004;811:93-101.
  61. McKinney AR, Richards SL, Cawley AT, Keledjian J, Wynne PM, Suann CJ. Catechol-O-methyltransferase inhibitors and the equine 3-methoxytyramine threshold. 2015:295-299.
  62. Elbourne M, Cawley A, Stanley S, Bowen C, Fu S. Intelligence benefit of the 3-methoxytyramine to tyramine ratio in equine urine. Drug Test Anal 2022.
  63. Duluard A, Bailly-Chouriberry L, Kieken F, Popot MA, Bonnaire Y. Longitudinal follow-up on racehorses: Veterinary and analytical issues. A one-year study of French trotters. 2012:27-34.
  64. Mooney MH, Le Bizec B, Elliott CT. Combining biomarker screening and mass-spectrometric analysis to detect hormone abuse in cattle. TrAC 2009;28:665-675.
  65. Doué M, Dervilly-Pinel G, Cesbron N. Clinical biochemical and hormonal profiling in plasma: a promising strategy to predict growth hormone abuse in cattle. Anal Bioanal Chem 2015;407:4343-4349.
  66. Capolongo F, Tapparo M, Merlanti R. Illicit treatments in cattle and urinary 6betahydroxycortisol/cortisol ratio. Anal Chim Acta 2007;586:228-232.
  67. Courant F, Pinel G, Bichon E, Monteau F, Antignac J-P, Le Bizec B. Development of a metabolomic approach based on liquid chromatography-high resolution mass spectrometry to screen for clenbuterol abuse in calves. Analyst 2009;134:1637-1646.
  68. Takayama T, Mochizuki T, Todoroki K. A novel approach for LC-MS/MS-based chiral metabolomics fingerprinting and chiral metabolomics extraction using a pair of enantiomers of chiral derivatization reagents. Anal Chim Acta 2015;898:73-84.
  69. Toyo'oka T. Derivatization-based high throughput bioanalysis by LC-MS. Anal Sci 2017;33:555-564.
  70. Leighton E, Sainsbury CAR, Jones GC. A practical review of c-peptide testing in diabetes. Diabetes Ther 2017;8:475-487.
  71. Lebowitz MR, Blumenthal SA. The molar ratio of insulin to C-peptide. An aid to the diagnosis of hypoglycemia due to surreptitious (or inadvertent) insulin administration. Arch Intern Med 1993;153:650-655.
  72. Thomas A, Yang R, Petring S, Bally L, Thevis M. Simplified quantification of insulin, its synthetic analogs and C-peptide in human plasma by means of LC-HRMS. Drug Test Anal 2020;12:382-390.
  73. Thomas A, Benzenberg L, Bally L, Thevis M. Facilitated qualitative determination of insulin, its synthetic analogs, and C-peptide in human urine by means of LC-HRMS. Metabolites 2021;11:309.
  74. Steuer AE, Arnold K, Kamber D, Kraemer T. Suitability evaluation of new endogenous biomarkers for the identification of nitrite-based urine adulteration in mass spectrometry methods. Drug Test Anal 2019;11:230-239.
  75. Eisenbeiss L, Binz TM, Baumgartner MR, Kraemer T, Steuer AE. Cheating on forensic hair testing? Detection of potential biomarkers for cosmetically altered hair samples using untargeted hair metabolomics. Analyst (London) 2020;145:6586-6599.
  76. van den Berg RA, Hoefsloot HCJ, Westerhuis JA, Smilde AK, van der Werf MJ. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 2006;7:142.

Citations

This article has been cited 1 times.
  1. Cloteau C, Dervilly G, Loup B, Delcourt V, Kaabia Z, Bagilet F, Groseille G, Dauriac K, Fisher S, Popot MA, Garcia P, Le Bizec B, Bailly-Chouriberry L. Performance assessment of an equine metabolomics model for screening a range of anabolic agents.. Metabolomics 2023 Apr 7;19(4):38.
    doi: 10.1007/s11306-023-01985-0pubmed: 37027080google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.